348 related articles for article (PubMed ID: 21499120)
1. Stem cells for drug screening.
Laposa RR
J Cardiovasc Pharmacol; 2011 Sep; 58(3):240-5. PubMed ID: 21499120
[TBL] [Abstract][Full Text] [Related]
2. Cardiomyocytes derived from human pluripotent stem cells for drug screening.
Zeevi-Levin N; Itskovitz-Eldor J; Binah O
Pharmacol Ther; 2012 May; 134(2):180-8. PubMed ID: 22269465
[TBL] [Abstract][Full Text] [Related]
3. Cardiomyocytes derived from human embryonic stem cells - characteristics and utility for drug discovery.
Steel D; Hyllner J; Sartipy P
Curr Opin Drug Discov Devel; 2009 Jan; 12(1):133-40. PubMed ID: 19152222
[TBL] [Abstract][Full Text] [Related]
4. A novel purification method of murine embryonic stem cell- and human-induced pluripotent stem cell-derived cardiomyocytes by simple manual dissociation.
Shinozawa T; Furukawa H; Sato E; Takami K
J Biomol Screen; 2012 Jun; 17(5):683-91. PubMed ID: 22274911
[TBL] [Abstract][Full Text] [Related]
5. The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells.
Yokoo N; Baba S; Kaichi S; Niwa A; Mima T; Doi H; Yamanaka S; Nakahata T; Heike T
Biochem Biophys Res Commun; 2009 Sep; 387(3):482-8. PubMed ID: 19615974
[TBL] [Abstract][Full Text] [Related]
6. Generation and characterization of functional cardiomyocytes using induced pluripotent stem cells derived from human fibroblasts.
Gai H; Leung EL; Costantino PD; Aguila JR; Nguyen DM; Fink LM; Ward DC; Ma Y
Cell Biol Int; 2009 Nov; 33(11):1184-93. PubMed ID: 19729070
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological response of human cardiomyocytes derived from virus-free induced pluripotent stem cells.
Mehta A; Chung YY; Ng A; Iskandar F; Atan S; Wei H; Dusting G; Sun W; Wong P; Shim W
Cardiovasc Res; 2011 Sep; 91(4):577-86. PubMed ID: 21565833
[TBL] [Abstract][Full Text] [Related]
8. Human pluripotent stem cells for disease modelling and drug screening.
Maury Y; Gauthier M; Peschanski M; Martinat C
Bioessays; 2012 Jan; 34(1):61-71. PubMed ID: 22038777
[TBL] [Abstract][Full Text] [Related]
9. An introduction to induced pluripotent stem cells.
Hanley J; Rastegarlari G; Nathwani AC
Br J Haematol; 2010 Oct; 151(1):16-24. PubMed ID: 20666774
[TBL] [Abstract][Full Text] [Related]
10. Pluripotent Stem Cell-Based Platforms in Cardiac Disease Modeling and Drug Testing.
Shaheen N; Shiti A; Gepstein L
Clin Pharmacol Ther; 2017 Aug; 102(2):203-208. PubMed ID: 28718902
[TBL] [Abstract][Full Text] [Related]
11. Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform.
Denning C; Borgdorff V; Crutchley J; Firth KS; George V; Kalra S; Kondrashov A; Hoang MD; Mosqueira D; Patel A; Prodanov L; Rajamohan D; Skarnes WC; Smith JG; Young LE
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1728-48. PubMed ID: 26524115
[TBL] [Abstract][Full Text] [Related]
12. The case for induced pluripotent stem cell-derived cardiomyocytes in pharmacological screening.
Khan JM; Lyon AR; Harding SE
Br J Pharmacol; 2013 May; 169(2):304-17. PubMed ID: 22845396
[TBL] [Abstract][Full Text] [Related]
13. Automated patch clamp on mESC-derived cardiomyocytes for cardiotoxicity prediction.
Stoelzle S; Haythornthwaite A; Kettenhofen R; Kolossov E; Bohlen H; George M; Brüggemann A; Fertig N
J Biomol Screen; 2011 Sep; 16(8):910-6. PubMed ID: 21775699
[TBL] [Abstract][Full Text] [Related]
14. ES and iPS cell research for cardiovascular regeneration.
Yamashita JK
Exp Cell Res; 2010 Oct; 316(16):2555-9. PubMed ID: 20385126
[TBL] [Abstract][Full Text] [Related]
15. Human stem cell-derived cardiomyocytes for pharmacological and toxicological modeling.
Harding SE
Ann N Y Acad Sci; 2011 Dec; 1245():48-9. PubMed ID: 22211978
[TBL] [Abstract][Full Text] [Related]
16. A Universal and Robust Integrated Platform for the Scalable Production of Human Cardiomyocytes From Pluripotent Stem Cells.
Fonoudi H; Ansari H; Abbasalizadeh S; Larijani MR; Kiani S; Hashemizadeh S; Zarchi AS; Bosman A; Blue GM; Pahlavan S; Perry M; Orr Y; Mayorchak Y; Vandenberg J; Talkhabi M; Winlaw DS; Harvey RP; Aghdami N; Baharvand H
Stem Cells Transl Med; 2015 Dec; 4(12):1482-94. PubMed ID: 26511653
[TBL] [Abstract][Full Text] [Related]
17. The application of human embryonic stem cell technologies to drug discovery.
Sartipy P; Björquist P; Strehl R; Hyllner J
Drug Discov Today; 2007 Sep; 12(17-18):688-99. PubMed ID: 17826681
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity testing using pluripotent stem cell-derived human cardiomyocytes and state-of-the-art bioanalytics: a review.
Mandenius CF; Steel D; Noor F; Meyer T; Heinzle E; Asp J; Arain S; Kraushaar U; Bremer S; Class R; Sartipy P
J Appl Toxicol; 2011 Apr; 31(3):191-205. PubMed ID: 21328588
[TBL] [Abstract][Full Text] [Related]
19. Protocols for cardiac differentiation of embryonic stem cells.
Pucéat M
Methods; 2008 Jun; 45(2):168-71. PubMed ID: 18593613
[TBL] [Abstract][Full Text] [Related]
20. Embryonic stem cells as a novel cell source of cell-based biosensors.
Liu Q; Huang H; Cai H; Xu Y; Li Y; Li R; Wang P
Biosens Bioelectron; 2007 Jan; 22(6):810-5. PubMed ID: 16621504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
